Compounds > indazoles
Page last updated: 2024-08-21

indazoles and losartan potassium

indazoles has been researched along with losartan potassium in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bae, JM; Choi, E; Chun, YS; Kim, MS; Park, JW; Teng, CM; Yeo, EJ1
Alexandre, I; Billemont, B; Meric, JB; Richard, S; Rixe, O1
Al-Mohanna, F; Alsmadi, O; DeNiro, M1
Dong, Y; Feng, D; Gao, G; Li, Y; Liu, D; Liu, H; Qin, H; Wang, J; Wen, H; Yin, Z; Zhao, D1
Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE1

Other Studies

5 other study(ies) available for indazoles and losartan potassium

ArticleYear
Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells.
    Biochemical pharmacology, 2001, Apr-15, Volume: 61, Issue:8

    Topics: Cell Hypoxia; Cyclic GMP; DNA-Binding Proteins; Drug Interactions; Endothelial Growth Factors; Enzyme Activators; Erythropoietin; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Lymphokines; Nuclear Proteins; Oxygen; Transcription Factors; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2001
Axitinib induces paradoxical erythropoietin synthesis in metastatic renal cell carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jan-20, Volume: 27, Issue:3

    Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Erythropoietin; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases

2009
Modulating the hypoxia-inducible factor signaling pathway as a therapeutic modality to regulate retinal angiogenesis.
    Experimental eye research, 2009, Volume: 89, Issue:5

    Topics: Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Cycle; Cell Hypoxia; Cell Movement; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Erythropoietin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Physiologic; Platelet Endothelial Cell Adhesion Molecule-1; Proteasome Endopeptidase Complex; Retinal Vessels; RNA, Messenger; Signal Transduction; Time Factors; Vascular Endothelial Growth Factor A; von Willebrand Factor

2009
Protective effect of HIF-1α against hippocampal apoptosis and cognitive dysfunction in an experimental rat model of subarachnoid hemorrhage.
    Brain research, 2013, Jun-23, Volume: 1517

    Topics: Animals; Apoptosis; Blood Pressure; Caspase 3; Cognition Disorders; Disease Models, Animal; DNA Fragmentation; Enzyme-Linked Immunosorbent Assay; Erythropoietin; Excitatory Amino Acid Transporter 2; Hippocampus; Hypoxia-Inducible Factor 1, alpha Subunit; Indazoles; Male; Maze Learning; Platelet Aggregation Inhibitors; Rats; Rats, Sprague-Dawley; Reaction Time; Subarachnoid Hemorrhage; Vascular Endothelial Growth Factor A

2013
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
    The oncologist, 2013, Volume: 18, Issue:8

    Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A

2013